Lonza: expansion of API facility
Lonza has announced a CHF 20m (about $21.6 USD) investment in expansion of its active pharmaceutical ingredient (API) development and manufacturing facility in Nansha, China. The project includes mid-scale manufacturing capabilities to help smooth transitions between early-phase and large-scale production.
Jan Vertommen, senior director of commercial development, said, “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. These companies need cost-effective, seamless ways to move small molecule compounds from early-phase to commercial according to global quality and regulatory standards, and these expanded facilities at our Nansha site are designed to help them to do so.”
